CIP2A and endometrial carcinoma: Analysis of human endometrial carcinoma TCGA data (n = 373)35, including 13, 4, and 4% patients with PPP2R1A, SET, and CIP2A mutations or altered mRNA levels, respectively, revealed that patients with these genetic or transcriptional alterations had increased mutation rate cluster, MSI status, and tumour mutation count (Supplementary Fig. 13).